Every New York stock exchange trading day I’m posting a daily dividend stock or fund review. I’ll share the three chief qualities of just one equity or fund that could be selected for a dividend stock portfolio I’ve named the Safari to Sweet Success.

This week’s slot in the Safari portfolio is reserved for the Healthcare sector.

That sector includes ten industries all related to testing, diagnosing and curing what ails us. The healthcare industries are: biotechnology; diagnostics & research; drug manufacturers – major; drug manufacturers – specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices, medial distribution; medical supplies.

Today I’m reviewing a drug manufacturing company in the specialty and generic industry named Hypermarcas S.A. Its trading ticker symbol is HYPMY.

Hypermarcas SA engages in the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Some of its prescription brands are Farmasa, Neo Quimica, and Luper.

Hypermarcas was founded in 2001 and is headquartered in Sao Paulo, Brazil.

I use three primary keys to measure dividend equities or funds like Hypermarcas S.A.(HYPMY): 

(1) Price

(2) Dividends

(3) Returns

These first three keys test whether the company has made, is making, and will continue to make money.

HYPMY Price

Hypermarcas S.A.’s price at yesterday’s market close was $11.09 per share. The company has positive momentum. Just a year ago its price was $8.24. That’s a gain of $2.85 in the past year.Can HYPMY do as well in the coming year?If it does, its price will increase from $11.09 to $13.95 per share or about 26 %.

HYPMY Dividends

The company’s most recent variable semi-annual dividend was $0.3951 declared in June 2017 and paid July 14th. 

The company has paid three dividends in North American winter, spring, and summer the past two years.